On July 19th, Gelunhui announced that its subsidiary, Shanghai Chungu Biomedical Technology Co., Ltd. ("Chungu Biotech"), has officially reached a strategic cooperation with Weigao Group Co., Ltd. ("Weigao Group") through the joint construction of multiple alliances, such as media cooperation promotion, park investment promotion, and industrial sharing and communication strategic service alliance, market acceleration service strategic alliance, scientific research and innovation alliance, and financial service innovation alliance. Both parties will synergistically stimulate more local innovation vitality, deeply promote the impact of Weigao Park and Weigao Group's high-quality products, and help Weigao Group's core competitiveness to continue to rise.

The medical industry in China is undergoing a transformation towards medical and health intelligence. Meisi Health is a leader in China's medical intelligence field and has always upheld the mission and vision of "improving medical quality" by providing precision digital medicine through big data and artificial intelligence. The Meisi Health platform currently has 5.1 million registered members, including 3.1 million certified medical users. With a huge platform of doctors, it empowers pharmaceutical companies to conduct accurate omni-channel marketing.

Weigao Group's main business is medical equipment and medicine, and it has 13 industrial groups, more than 100 subsidiaries, including 3 listed companies and 8 overseas companies. It has established 15 national and provincial innovation platforms, such as the national recognized enterprise technology center, the national engineering research center, the national innovation pilot enterprise, the academician workstation, the post-workstation, and the Taishan scholar laboratory. Meisi Health hopes to take full advantage of this cooperation opportunity, focus on their respective advantageous fields, match professional resources, provide innovative solutions for Weigao Group in multiple areas such as industry communication, media promotion, scientific research and innovation, and financial service innovation, and promote the digital transformation and intelligent upgrading of the medical industry.

In the future, Meisi Health will also adhere to the dual drive of medicine and digitization as the core gene of Meisi, based on professional medical information, precise digital technology, and the full and effective combination of the two, join hands with peers in the industry to jointly establish an ecosystem, eliminate imbalances, and help the high-quality development of the overall medical and pharmaceutical industry and create a better life.